The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura.

The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura.

Item
http://www.wikidata.org/entity/Q33372348
Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research.Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.Understanding organ dysfunction in thrombotic thrombocytopenic purpura.A novel homozygous frameshift mutation in Exon 7 of the ADAMTS13 gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report.
P2860

The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura.

Item
http://www.wikidata.org/entity/Q33372348
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The use of intermediate purity ...... otic thrombocytopenic purpura.
@ast
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
type
label
The use of intermediate purity ...... otic thrombocytopenic purpura.
@ast
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
prefLabel
The use of intermediate purity ...... otic thrombocytopenic purpura.
@ast
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2141.2006.06264.X
P407
P433
P478
P577
P5875
P698
P921